Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDXNASDAQ:GYRENASDAQ:NTLANASDAQ:PVLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$3.97+0.3%$4.53$3.21▼$8.06$949.84M0.764.46 million shs2.57 million shsGYREGyre Therapeutics$8.68-22.6%$9.00$6.11▼$19.00$813.82M1.9105,063 shs2.11 million shsNTLAIntellia Therapeutics$9.16-3.2%$7.98$5.90▼$28.18$948.82M2.332.56 million shs2.18 million shsPVLAPalvella Therapeutics$23.72+7.3%$24.12$6.20▼$29.27$261.94M0.168,642 shs138,230 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+0.25%+2.32%-18.14%-21.46%-49.23%GYREGyre Therapeutics-22.57%-23.52%-5.55%-24.78%-35.89%NTLAIntellia Therapeutics-3.17%+7.76%+13.02%-24.73%-64.73%PVLAPalvella Therapeutics+7.28%+7.57%-10.69%+23.41%+2,371,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.3887 of 5 stars4.52.00.04.41.92.50.6GYREGyre Therapeutics0.3784 of 5 stars0.02.00.00.02.41.70.0NTLAIntellia Therapeutics4.6221 of 5 stars4.31.00.04.73.82.51.3PVLAPalvella Therapeutics3.793 of 5 stars4.60.00.00.02.84.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 2.90Moderate Buy$10.39161.68% UpsideGYREGyre Therapeutics 3.00BuyN/AN/ANTLAIntellia Therapeutics 2.67Moderate Buy$36.90302.84% UpsidePVLAPalvella Therapeutics 3.13Buy$46.2995.13% UpsideCurrent Analyst Ratings BreakdownLatest PVLA, GYRE, ARDX, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/19/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.005/16/2025PVLAPalvella TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$53.00 ➝ $52.005/12/2025NTLAIntellia TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $45.005/9/2025NTLAIntellia TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $10.005/9/2025NTLAIntellia TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$68.00 ➝ $68.005/2/2025ARDXArdelyxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.005/2/2025ARDXArdelyxRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$11.004/30/2025PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/21/2025NTLAIntellia TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$21.004/9/2025PVLAPalvella TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$361.71M2.63N/AN/A$0.73 per share5.44GYREGyre Therapeutics$100.64M8.09$0.17 per share50.49$0.18 per share48.22NTLAIntellia Therapeutics$45.57M20.82N/AN/A$11.73 per share0.78PVLAPalvella Therapeutics$42.81M6.12N/AN/A$21.66 per share1.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.22N/A12.81N/A-11.73%-24.87%-10.51%8/7/2025 (Estimated)GYREGyre Therapeutics-$92.93M$0.02434.00∞N/A-84.57%-118.43%-71.97%8/12/2025 (Estimated)NTLAIntellia Therapeutics-$481.19M-$5.23N/AN/AN/AN/A-49.34%-40.27%N/APVLAPalvella Therapeutics-$24.54M-$12.10N/AN/AN/AN/A-80.93%-59.55%N/ALatest PVLA, GYRE, ARDX, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PVLAPalvella Therapeutics-$3.40-$0.74+$2.66-$0.74N/AN/A5/9/2025Q1 2025GYREGyre Therapeutics$0.03$0.03N/AN/A$28.40 million$22.06 million5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 million5/1/2025Q1 2025ARDXArdelyx-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million3/17/2025Q4 2024GYREGyre Therapeutics$0.04$0.01-$0.03$0.02$23.50 million$27.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx0.874.584.31GYREGyre TherapeuticsN/A3.723.29NTLAIntellia TherapeuticsN/A6.736.73PVLAPalvella TherapeuticsN/A4.824.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%GYREGyre Therapeutics23.99%NTLAIntellia Therapeutics88.77%PVLAPalvella Therapeutics40.11%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%GYREGyre Therapeutics19.52%NTLAIntellia Therapeutics3.10%PVLAPalvella Therapeutics20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90239.26 million222.88 millionOptionableGYREGyre Therapeutics4093.76 million75.27 millionNo DataNTLAIntellia Therapeutics600103.58 million98.59 millionOptionablePVLAPalvella TherapeuticsN/A11.04 million10.50 millionN/APVLA, GYRE, ARDX, and NTLA HeadlinesRecent News About These CompaniesAnalyzing Palvella Therapeutics (NASDAQ:PVLA) and Statera Biopharma (NASDAQ:STAB)May 24 at 1:53 AM | americanbankingnews.comCantor Fitzgerald Predicts PVLA FY2025 EarningsMay 23 at 8:29 AM | marketbeat.comFrazier Life Sciences Management L.P. Invests $7.85 Million in Palvella Therapeutics (NASDAQ:PVLA)May 23 at 7:51 AM | marketbeat.comCresset Asset Management LLC Purchases New Holdings in Palvella Therapeutics (NASDAQ:PVLA)May 20, 2025 | marketbeat.comSuvretta Capital Management LLC Takes $8.57 Million Position in Palvella Therapeutics (NASDAQ:PVLA)May 19, 2025 | marketbeat.comCanaccord Genuity Group Cuts Palvella Therapeutics (NASDAQ:PVLA) Price Target to $52.00May 19, 2025 | americanbankingnews.comBrokerages Set Palvella Therapeutics (NASDAQ:PVLA) Price Target at $44.43May 19, 2025 | americanbankingnews.comWhy Palvella Therapeutics, Inc.’s (PVLA) Stock Is Up 5.55%May 16, 2025 | aaii.comPromising Outlook for Palvella Therapeutics: Buy Rating Affirmed by Andrew Fein Due to Phase 3 SELVA Trial Success and Strategic Market PositionMay 16, 2025 | tipranks.comPalvella Therapeutics Inc (PVLA) Q1 2025 Earnings Call Highlights: Strong Clinical Progress ...May 16, 2025 | finance.yahoo.comPalvella Therapeutics (NASDAQ:PVLA) Given Average Recommendation of "Buy" by AnalystsMay 16, 2025 | marketbeat.comQ1 2025 Palvella Therapeutics Inc Earnings Call TranscriptMay 16, 2025 | gurufocus.comPalvella Therapeutics Inc.: Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | finanznachrichten.dePalvella Therapeutics: Q1 Earnings SnapshotMay 15, 2025 | timesunion.comPromising Outlook for Palvella Therapeutics: Buy Rating Backed by Strong Financials and Innovative QTORIN PlatformMay 15, 2025 | tipranks.comPalvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | globenewswire.comPalvella Therapeutics (PVLA) Expected to Announce Quarterly Earnings on ThursdayMay 14, 2025 | americanbankingnews.comPalvella Therapeutics Rings the Opening BellMay 13, 2025 | nasdaq.comPalvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor CallMay 12, 2025 | msn.com71,452 Shares in Palvella Therapeutics (NASDAQ:PVLA) Bought by DAFNA Capital Management LLCMay 10, 2025 | marketbeat.comPalvella Therapeutics to Ring Nasdaq Opening BellMay 9, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePVLA, GYRE, ARDX, and NTLA Company DescriptionsArdelyx NASDAQ:ARDX$3.97 +0.01 (+0.25%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.96 -0.01 (-0.13%) As of 05/23/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Gyre Therapeutics NASDAQ:GYRE$8.68 -2.53 (-22.57%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$8.98 +0.30 (+3.50%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Intellia Therapeutics NASDAQ:NTLA$9.16 -0.30 (-3.17%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$9.13 -0.03 (-0.33%) As of 05/23/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Palvella Therapeutics NASDAQ:PVLA$23.72 +1.61 (+7.28%) As of 05/23/2025 04:00 PM EasternPalvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
